What are the cardiovascular outcomes of oral diabetes medications?
According to a systematic review published in the Archives of Internal Medicine, the cardiovascular outcomes of oral diabetes medications can vary. Specifically, the review found that certain medications, such as thiazolidinediones, may increase the risk of cardiovascular disease in some patients, while other medications, such as metformin, may reduce the risk of cardiovascular disease. Additionally, the UK Prospective Diabetes Study (UKPDS) found that intensive blood-glucose control with metformin can reduce the risk of complications in overweight patients with type 2 diabetes. These findings are further supported by the American Diabetes Association's Standards of Medical Care in Diabetes for 2011. 